U.S. to announce prices for drugs in Medicare negotiations, NY Times says

The Biden administration is set to announce the results of price negotiations between Medicare and the pharmaceutical companies over the prices of 10 common medications taken by older Americans, Noah Weiland and Rebecca Robbins of The New York Times reports. The prices of the drugs, which include blood thinners and arthritis medications, will take effect in 2026 and represents the first time the federal government has directly negotiated with drugmakers on behalf of Medicare beneficiaries. Drugs subjected to negotiation include Eliquis, from Bristol Myers Squibb (BMY) and Pfizer (PFE); Jardiance, from Boehringer Ingelheim and Eli Lilly (LLY); Xarelto, from Johnson & Johnson (JNJ); Januvia, from Merck (MRK); Farxiga, from AstraZeneca (AZN); Entresto, from Novartis (NVS); Enbrel, from Amgen (AMGN); Imbruvica, from AbbVie (ABBV) and Johnson & Johnson; Stelara, from Johnson & Johnson; and Fiasp and NovoLog from Novo Nordisk (NVO).